Listeria
Related VF: LLO (Listeriolysin O)
Target: Hly
Drug effect: A potent inhibitor of LLO pore formation and MyD88-dependent inflammation response.
Max phase: Preclinical (in vivo)
Publication: Wang T, et al., 2022. Kaempferol-Driven Inhibition of Listeriolysin O Pore Formation and Inflammation Suppresses Listeria monocytogenes Infection. Microbiol Spectr 10(4):e0181022.
Streptococcus
Related VF: Pneumolysin
Target: Ply
Drug effect: Interferes with the pore-forming activity of Pneumolysin by engaging with catalytic active sites to inhibit Pneumolysin-mediated cytotoxicity and reduces the SrtA peptidase activity by occupying the active sites of SrtA.
Max phase: Preclinical (in vivo)
Publication: Xu L, et al., 2023. Therapeutic potential of kaempferol on Streptococcus pneumoniae infection. Microbes Infect 25(3):105058.